Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PRT-3789 by Prelude Therapeutics for Esophageal Cancer: Likelihood of Approval
PRT-3789 is under clinical development by Prelude Therapeutics and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase...
PRT-3789 by Prelude Therapeutics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
PRT-3789 is under clinical development by Prelude Therapeutics and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to...
PRT-3789 by Prelude Therapeutics for Breast Cancer: Likelihood of Approval
PRT-3789 is under clinical development by Prelude Therapeutics and currently in Phase I for Breast Cancer. According to GlobalData, Phase...
PRT-3789 by Prelude Therapeutics for Ovarian Cancer: Likelihood of Approval
PRT-3789 is under clinical development by Prelude Therapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
PRT-3789 by Prelude Therapeutics for Colorectal Cancer: Likelihood of Approval
PRT-3789 is under clinical development by Prelude Therapeutics and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...
PRT-3789 by Prelude Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
PRT-3789 is under clinical development by Prelude Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...
PRT-3789 by Prelude Therapeutics for Solid Tumor: Likelihood of Approval
PRT-3789 is under clinical development by Prelude Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...